

## **Zydus receives final approval from the USFDA for Azithromycin for Oral Suspension USP**

---

*Ahmedabad, 01 August, 2018*

Zydus Cadila has received the final approval from the USFDA to market Azithromycin for Oral Suspension USP (US RLD - Zithromax), 100 mg/5 mL and 200 mg/5 mL.

This medication contains Azithromycin, a macrolide antibiotic that fights bacteria. It is used to treat different types of bacterial infections such as respiratory infections, skin infections, ear infections and sexually transmitted diseases. This medication will not work for viral infections such as common cold, flu etc. The drug will be manufactured at the group's formulations manufacturing facility at Baddi.

In line with this, the group now has 213 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*